drugset / Trial / NCT00417118
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder. The secondary objectives are to evaluate the efficacy of saredutant on disability and quality of life in patients with generalized anxiety disorder, and to evaluate blood levels of saredutant.
Timeline
- Start
- 2006-12
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Escitalopram | Small molecule | 10 mg | Oral |
| Subject | Saredutant | Small molecule | 100 mg | Oral |